High-Valency Enveloped Particle Display With Human Oligomerization Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in effectively targeting multivalent interactions involved in disease pathogenesis, as they often fail to mimic the multivalent targets and counteract them through antagonism or agonism, leading to inefficiencies in drug delivery.
Innovation Solution
Recombinant fusion proteins comprising transmembrane domains, display polypeptides, and human oligomerization domains, such as coiled coil motifs, are expressed on enveloped particles to create high valency oligomeric formats, mimicking multivalent targets and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent approaches are used for drug delivery, then the treatment is simpler to administer, but the therapeutic efficacy is insufficient due to inability to mimic multivalent targets
Solution Approach 1:
The fusion protein is divided into distinct functional segments: oligomerization domain (for multivalent assembly), transmembrane domain (for particle anchoring), and display polypeptide (for target interaction). This segmentation allows each domain to independently fulfill its function while contributing to overall therapeutic efficacy.
Solution Approach 2:
The invention creates a composite molecular structure by combining multiple protein domains with different functions into a single fusion protein. This composite approach enables the molecule to simultaneously achieve multivalent oligomerization, membrane anchoring, and specific target binding, thereby enhancing therapeutic efficacy.
2Reliability
If high valency oligomeric formats are expressed on enveloped particles, then the ability to mimic and counteract multivalent targets is enhanced, but the manufacturing complexity increases
Solution Approach 1:
The fusion protein design achieves multi-functionality by integrating oligomerization, membrane anchoring, and target binding capabilities into a single molecule. This universal design allows the same basic structure to target different diseases by simply changing the display polypeptide while maintaining the core oligomerization and transmembrane domains.
Solution Approach 2:
The oligomerization domain enables controlled adjustment of valency parameters (dimer, trimer, tetramer configurations). By changing the oligomerization state, the therapeutic can be optimized for different target geometries and binding affinities, providing a tunable platform for various applications.
3Reliability
If existing technologies are used to target multivalent interactions, then the approach is simpler, but the ability to effectively counteract disease pathogenesis is compromised
Solution Approach 1:
The fusion protein is designed to preemptively counteract multivalent pathogenic interactions by mimicking the target structure. The oligomeric display polypeptide binds to multiple sites on the target simultaneously, blocking pathogenic binding before it can occur, thereby preventing disease progression.
Data Source
AI summary
Disclosed herein are recombinant fusion protein comprising transmembrane domains, display polypeptides, and human oligomerization domains, and enveloped particles containing the same, and methods of use.